ImmunoCellular Therapeutics (NASDAQ:IMUC)‘s stock had its “buy” rating restated by equities researchers at Summer Street in a research report issued on Thursday, American Banking News.com reports. A number of other analysts have also recently weighed in on IMUC. Analysts at Roth Capital downgraded shares of ImmunoCellular Therapeutics from a “buy” rating to a “neutral” rating […]
ImmunoCellular Therapeutics Receives Buy Rating from Summer Street (IMUC) is a post from: Zolmax
The post ImmunoCellular Therapeutics Receives Buy Rating from Summer Street (IMUC) appeared first on Zolmax.